Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.67 EUR | -4.44% |
|
+1.99% | +55.84% |
07-04 | OSE: program with Boehringer Ingelheim to continue | CF |
07-04 | OSE Immunotherapeutics, Boehringer Ingelheim's Cancer Drug to Enter Phase 1b Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.84% | 166M | |
+22.15% | 46.56B | |
+45.32% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- OSE Immunotherapeutics, Boehringer Ingelheim's Cancer Drug to Enter Phase 1b Study